Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target

Chit Cheng Yeoh; Nedal Dabab; Elyse Rigby; Ritu Chhikara; Iolia Akaev; Ricardo Santiago Gomez; Felipe Fonseca; Peter A. Brennan; Siavash Rahimi

doi:10.1111/jop.12741

Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target

Chit Cheng Yeoh, Nedal Dabab, Elyse Rigby, Ritu Chhikara, Iolia Akaev, Ricardo Santiago Gomez, Felipe Fonseca, Peter A. Brennan, Siavash Rahimi

Institute of Life Sciences and Healthcare

Research output: Contribution to journal › Article › peer-review

25 Downloads (Pure)

Abstract

The role of the androgen receptor (AR) as an immunomarker for diagnosis of salivary gland duct carcinoma (SDC) is well known. Other non‐squamous cell head and neck cancers (NSCC‐HN), including a small subset of salivary gland cancers (SGCs), can also express AR. With the increase in effective and powerful new generation of anti‐androgen agents and drugs administered orally, more targetable AR‐driven NSCC‐HN, such as subsets of SGCs, should be investigated for possible expression of AR. In this review, we focus on SGC subtypes, which could express AR and describe the main androgen deprivation therapy (ADT) strategies.

Original language	English
Pages (from-to)	691-695
Number of pages	5
Journal	Journal of Oral Pathology & Medicine
Volume	47
Issue number	7
Early online date	28 Jun 2018
DOIs	https://doi.org/10.1111/jop.12741
Publication status	Published - 1 Aug 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

abiraterone
androgen receptor
enzalutamide
head and neck
immunihistochemistry
non-squamous cell carcinoma
salivary gland carcinoma

Access to Document

10.1111/jop.12741

Androgen_Receptor_in_Salivary_Gland
This is the peer reviewed version of the following article: Yeoh CC, Dabab N, Rigby E, et al. Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target. J Oral Pathol Med. 2018; 47: 691–695. , which has been published in final form at https://doi.org/10.1111/j.1600-0714.2018.12741.x.
Accepted author manuscript (Post-print), 444 KB

Cite this

@article{23eca030ddf1465dacc5b5f3c2b7d149,

title = "Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target",

abstract = "The role of the androgen receptor (AR) as an immunomarker for diagnosis of salivary gland duct carcinoma (SDC) is well known. Other non‐squamous cell head and neck cancers (NSCC‐HN), including a small subset of salivary gland cancers (SGCs), can also express AR. With the increase in effective and powerful new generation of anti‐androgen agents and drugs administered orally, more targetable AR‐driven NSCC‐HN, such as subsets of SGCs, should be investigated for possible expression of AR. In this review, we focus on SGC subtypes, which could express AR and describe the main androgen deprivation therapy (ADT) strategies.",

keywords = "abiraterone, androgen receptor, enzalutamide, head and neck, immunihistochemistry, non-squamous cell carcinoma, salivary gland carcinoma",

author = "Yeoh, \{Chit Cheng\} and Nedal Dabab and Elyse Rigby and Ritu Chhikara and Iolia Akaev and Gomez, \{Ricardo Santiago\} and Felipe Fonseca and Brennan, \{Peter A.\} and Siavash Rahimi",

year = "2018",

month = aug,

day = "1",

doi = "10.1111/jop.12741",

language = "English",

volume = "47",

pages = "691--695",

journal = "Journal of Oral Pathology \& Medicine",

issn = "0904-2512",

publisher = "Wiley-Blackwell",

number = "7",

}

TY - JOUR

T1 - Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target

AU - Yeoh, Chit Cheng

AU - Dabab, Nedal

AU - Rigby, Elyse

AU - Chhikara, Ritu

AU - Akaev, Iolia

AU - Gomez, Ricardo Santiago

AU - Fonseca, Felipe

AU - Brennan, Peter A.

AU - Rahimi, Siavash

PY - 2018/8/1

Y1 - 2018/8/1

N2 - The role of the androgen receptor (AR) as an immunomarker for diagnosis of salivary gland duct carcinoma (SDC) is well known. Other non‐squamous cell head and neck cancers (NSCC‐HN), including a small subset of salivary gland cancers (SGCs), can also express AR. With the increase in effective and powerful new generation of anti‐androgen agents and drugs administered orally, more targetable AR‐driven NSCC‐HN, such as subsets of SGCs, should be investigated for possible expression of AR. In this review, we focus on SGC subtypes, which could express AR and describe the main androgen deprivation therapy (ADT) strategies.

AB - The role of the androgen receptor (AR) as an immunomarker for diagnosis of salivary gland duct carcinoma (SDC) is well known. Other non‐squamous cell head and neck cancers (NSCC‐HN), including a small subset of salivary gland cancers (SGCs), can also express AR. With the increase in effective and powerful new generation of anti‐androgen agents and drugs administered orally, more targetable AR‐driven NSCC‐HN, such as subsets of SGCs, should be investigated for possible expression of AR. In this review, we focus on SGC subtypes, which could express AR and describe the main androgen deprivation therapy (ADT) strategies.

KW - abiraterone

KW - androgen receptor

KW - enzalutamide

KW - head and neck

KW - immunihistochemistry

KW - non-squamous cell carcinoma

KW - salivary gland carcinoma

UR - http://doi.wiley.com/10.1111/jop.12741

U2 - 10.1111/jop.12741

DO - 10.1111/jop.12741

M3 - Article

SN - 0904-2512

VL - 47

SP - 691

EP - 695

JO - Journal of Oral Pathology & Medicine

JF - Journal of Oral Pathology & Medicine

IS - 7

ER -

Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this